Single and Repeat Doses of DMT in Healthy Subjects

This double-blind trial (n=60) by Algernon Pharmaceuticals will give participants several 6-hour (you read that right) infusions of DMT. The first part will start with a 1.5mg bolus followed by 6.3mg (0.105mg p/m) each hour. If read correctly, the second part of the study will do six doses over six hours but doesn’t specify if a continuous infusion will also be given.

Topic Healthy Subjects
Compound DMT
Country Netherlands
Visit trial
Status Not yet recruiting
Results Published
Start date 01 November 2022
End date 01 May 2023
Chance of happening 100%
Phase Phase I
Design Blinded
Type Interventional
Generation First
Participants 60
Sex All
Age 18- 60
Therapy No

Trial Details

This study aims to assess the safety and tolerability of single ascending, and fixed repeated doses of N,N-Dimethyltryptamine (DMT) in healthy subjects, when given by intravenous (IV) infusion.

NCT Number NCT05559931

Sponsors & Collaborators

Algernon Pharmaceuticals
Algernon is a clinical stage pharmaceutical company that is developing novel psychedelic molecules (based on DMT) for the treatment of stroke-related dysfunction.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.